Coronary Stent Market By Type (Bare-Metal Stents (BMS), Drug-Eluting Stents (DES)), By Material Type (Polymer-Based Stents, Metallic Stents), By End User (Cardiac Centers, Hospitals) And Region For 2024-2031

Coronary Stent Market Valuation - 2024-2031

The global demand for coronary stents has been steadily increasing, driven primarily by the rising prevalence of cardiovascular diseases and advancements in stent technology. Cardiovascular disease remains a leading cause of death worldwide, with contributing factors such as sedentary lifestyles, unhealthy diets, smoking, and aging populations in developed and developing regions. As the incidence of coronary artery disease rises, so does the need for effective treatment options, propelling the market for coronary stents. The market size surpass USD 7.11 Billion valued in 2023 to reach a valuation of aroundUSD 13.87 Billion by 2031.

Innovations in stent technology, including drug-eluting stents and bioresorbable vascular scaffolds, have made these devices safer and more effective, further supporting their increased adoption in the medical community. The rising demand for cost-effective and efficient coronary stent is enabling the market grow at aCAGR of 8.71% from 2024 to 2031.

Coronary Stent Market: Definition/ Overview

A coronary stent is a small, metal mesh tube used to treat narrowed or blocked coronary arteries, which supply blood to the heart. It is typically implanted during a procedure known as percutaneous coronary intervention (PCI) or angioplasty. Coronary stents are designed to restore blood flow by supporting the artery walls, reducing the risk of chest pain, heart attacks, and other complications associated with coronary artery disease (CAD). There are several types of coronary stents, including bare-metal stents, drug-eluting stents (DES), and bioresorbable stents, each offering unique benefits in terms of safety, efficacy, and longevity.

Coronary stents is promising, driven by advancements in stent technology, growing demand for minimally invasive procedures, and the increasing prevalence of CAD. Emerging innovations, such as bioresorbable and nanotechnology-based stents, are expected to improve long-term outcomes by reducing complications like restenosis and thrombosis. Additionally, as the aging population grows and healthcare access improves globally, particularly in developing regions, the demand for coronary stents is likely to rise, creating new growth opportunities in the market.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Drive the Coronary Stent Market?

The rising prevalence of cardiovascular diseases (CVD) is significantly driving the coronary stent market, primarily due to the growing need for effective treatment options to manage and alleviate coronary artery blockages. With cardiovascular diseases causing 17.9 million deaths globally each year, according to the WHO, and coronary heart disease affecting around 18.2 million U.S. adults, as reported by the CDC, the demand for coronary stenting procedures has surged. This increasing patient pool necessitates advanced and accessible stent solutions, driving market growth as healthcare systems aim to reduce CVD-related morbidity and mortality.

The growing elderly population is indeed fueling the coronary stent market. As age is a primary risk factor for coronary artery disease, the rising number of elderly individuals directly increases the demand for coronary stents. According to the United Nations, the global population aged 65 and above is expected to reach 1.5 billion by 2050, with developing regions seeing the fastest growth. In the EU, nearly 20% of all percutaneous coronary interventions (PCIs) target patients aged 75 or older, illustrating a clear link between aging populations and increased stent procedures.

Will the High-Cost impact the Growth of the Coronary Stent Market?

The high cost of coronary stents can impact the growth of the coronary stent market. The expense of stent procedures, particularly for advanced drug-eluting stents, can be prohibitive for patients and healthcare systems, especially in low- and middle-income countries where budget constraints and limited healthcare coverage are prevalent. These costs also impact insurance premiums, making stent procedures less accessible, which can slow the adoption rate and market growth despite the increasing demand driven by aging populations and rising cardiovascular disease prevalence.

The risk of complications can impact the growth of the coronary stent market. Complications such as stent thrombosis, restenosis, and bleeding pose significant health risks, which can lead to additional procedures, increased medical costs, and patient hesitancy. Concerns over these potential complications may prompt healthcare providers to consider alternative treatments, thus limiting the market's growth despite advancements in stent technology aimed at minimizing these risks.

Category-Wise Acumens

Will the Reduced Restenosis Raise the Drug-Eluting Stents (DES) Segment for the Coronary Stent Market?

Drug-Eluting Stents (DES) Segment is dominating the coronary stent market. Reduced restenosis rates are likely to propel the growth of the Drug-Eluting Stents (DES) segment in the coronary stent market. DES is designed to release medication that inhibits cell proliferation, significantly reducing the risk of restenosis compared to bare-metal stents. This improved efficacy in preventing artery re-narrowing makes DES a preferred choice for patients and healthcare providers, driving higher adoption rates and supporting market growth in this segment.

Technological advancements are propelling the drug-eluting stents (DES) segment within the coronary stent market. Innovations such as improved biocompatible polymers, biodegradable stents, and advanced drug coatings have enhanced the safety and effectiveness of DES, reducing complications like restenosis and improving patient outcomes. These advancements make DES an increasingly preferred choice among healthcare providers, driving growth within this segment as they seek safer and more effective solutions for coronary artery disease.

Will the Proven Efficacy Fuel the Metallic Stents Segment for the Coronary Stent Market?

The metallic stents segment is ruling the coronary stent market. The proven efficacy of metallic stents is promoting growth in this segment of the coronary stent market. Metallic stents, particularly drug-eluting and bare-metal stents, have shown reliable results in maintaining vessel patency and reducing the risk of acute complications. Their durability and established clinical success make them a trusted choice for many cardiologists, especially in complex cases, driving continued demand and growth within this segment as they offer consistent and effective treatment for coronary artery disease.

Cost-effectiveness is promoting the metallic stents segment within the coronary stent market. Metallic stents, especially bare-metal stents, offer a more affordable option compared to drug-eluting or biodegradable stents, making them attractive for patients and healthcare systems in cost-sensitive regions. Their durability and relatively lower cost make metallic stents a practical choice for managing coronary artery disease, thus driving demand in regions with budget constraints or limited healthcare funding.

Country/Region-wise Acumens

Will the Rising Prevalence of Cardiovascular Diseases (CVD) Accelerate the North American Region for Coronary Stent Market?

North America's dominance in the coronary stent market. The rising prevalence of cardiovascular diseases (CVD) is likely to accelerate the coronary stent market' in North America. With about 20.1 million adults aged 20 and older currently affected by coronary artery disease (CAD) and an expected increase to 28.5 million by 2040, there is a growing demand for coronary stents. This demand stems from the need for effective treatment options, as coronary stents play a critical role in managing CAD by improving blood flow and reducing the risk of severe cardiac events, thereby driving market growth.

The advanced healthcare infrastructure in North America is accelerating the growth of the coronary stent market. The region's extensive network of around 6,090 hospitals in the U.S. alone enables widespread access to cardiac procedures, with over 1 million coronary stent procedures performed annually. This accessibility, combined with skilled healthcare professionals and advanced medical technologies, ensures timely treatment for cardiovascular diseases, thereby driving demand and growth in the coronary stent market.

Will the Large Patient Pool Expand the Asia Pacific Region for the Coronary Stent Market?

Asia Pacific is rapidly growing in the coronary stent market due to several factors. The large patient pool in the Asia Pacific region is significantly escalating the growth of the coronary stent market. The region accounts for nearly 60% of the global cardiovascular disease burden, as reported by the Asian Pacific Society of Cardiology. Additionally, Japan's aging population, with 27.6% affected by cardiovascular diseases, highlights the demand for coronary interventions. This high prevalence, combined with the growing need for accessible treatment options, drives the expansion of the coronary stent market in Asia Pacific.

The growing disease burden is significantly escalating the coronary stent market in the Asia Pacific region. With China reporting over 330 million patients with cardiovascular diseases and India expecting its coronary artery disease cases to rise from 65.1 million to 75 million by 2030, the demand for coronary stents is increasing. This high prevalence of cardiovascular conditions is driving the need for coronary stent procedures, as healthcare providers seek effective treatments to manage the rising cases and improve patient outcomes across the region.

Competitive Landscape

The coronary stent market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the coronary stent market include:

• Abbott Laboratories, Boston Scientific, Medtronic, Terumo Corporation, Braun Melsungen, Cook Medical, Biosensors International, Biotronik, Johnson & Johnson, Meril Life Sciences

Latest Developments

• In April 2021, Abbott announced the launched of coronary imaging platform Ultreon 1.0 Software powered by AI in Europe. The software has been launched with an aim to improve detection of calcium-based blockages and measure vessel diameter during coronary stenting procedures.
• In February 2021, Cardiovascular Systems Inc established a partnership with Chansu Vascular Technologies, LLC to produce peripheral and coronary drug-coated balloons for use in drug-eluting stents.